Loading...
•
Mar 31, 2022
TransMedics Q1 2022 Earnings Report
TransMedics' first quarter results for 2022 showed significant revenue growth driven by the National OCS Program.
Key Takeaways
TransMedics reported a strong first quarter with net revenue of $15.9 million, a 125% increase compared to the same period in 2021. The growth was primarily driven by increased commercial sales of OCS Heart and OCS Liver in the United States. The company is updating its full year 2022 net revenue guidance to be in the range of $59 million to $65 million.
Net revenue reached $15.9 million, marking a 125% increase compared to Q1 2021.
FDA pre-market approval was received for the OCS™ DCD heart indication on April 28, 2022.
Data from the U.S. randomized OCS™ DCD Heart trial and OCS™ Lung Trial 5-year data were presented at the International Society of Heart and Lung Transplantation (ISHLT) annual meeting.
The National OCS™ Program (NOP) was the primary growth driver.
Forward Guidance
TransMedics is updating full year 2022 net revenue to be in the range of $59 million to $65 million, which represents 95% to 115% growth compared to the company’s prior year net revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...